Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01673438 · ClinicalTrials.gov registry record · Phase 1

Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by ImmunityBio.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT01673438 is a Phase 1 study of Advanced Solid Tumor that has completed, run by ImmunityBio. The registered enrollment target is 15 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01673438, a Phase 1 study of Advanced Solid Tumor, has completed, sponsored by ImmunityBio.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This is a phase 1b open-label study to investigate the safety and maximum tolerated dose of aldoxorubicin plus doxorubicin HCl adminstered as infusion every 3 weeks for up to 8 cycles in subjects with advance solid tumors.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG aldoxorubicin

Study Locations (1)

California

  • Sarcoma Oncology Center - Santa Monica

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2012-07
Est. Completion 2014-04
Phase Phase 1

Sponsor

ImmunityBio

46 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01673438

The ClinicalTrials.gov registry entry for NCT01673438 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (92% lower). The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which aldoxorubicin is the first listed.

NCT01673438 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01673438 about?

NCT01673438 is a clinical study titled "Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors". This is a phase 1b open-label study to investigate the safety and maximum tolerated dose of aldoxorubicin plus doxorubicin HCl adminstered as infusion every 3 weeks for up to 8 cycles in subjects with advance solid tumors.

What is the current status of trial NCT01673438?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2012-07. Estimated completion is 2014-04.

What conditions does trial NCT01673438 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT01673438?

The interventions under investigation include: aldoxorubicin (DRUG).

Who is sponsoring clinical trial NCT01673438?

This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01673438 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.